Abstract
Background
Vogt-Koyanagi-Harada (VKH) syndrome is characterized by bilateral diffuse uveitis associated with auditory, neurological, and cutaneous signs and symptoms. VKH syndrome is a cell-mediated autoimmune disease against melanocytes. Choroidal neovascularization (CNV) occurs in 15% of VKH patients and is associated with poor visual prognosis.
Cases
We report on two patients with VKH syndrome and CNV that were treated with intravitreal bevacizumab.
Observations
One of the VKH patients also had an extrafoveal CNV membrane and underwent multiple intravitreal injections of bevacizumab in combination with laser photocoagulation, with subsequent improvement in visual acuity. The second had a subfoveal CNV that responded to a single intravitreal injection of bevacizumab.
Conclusion
Intravitreal bevacizumab may be a useful drug to treat CNV in eyes with VKH syndrome.
This is a preview of subscription content, log in via an institution to check access.
References
Read RW, Rechodouni A, Butani N, et al. Complications and prognostic factors in Vogt-Koyanagi-Harada disease. Am J Ophthalmol 2001;131:599–606.
Lertsumitkul S, Whitcup SM, Nussenblatt RB, Chan CC. Subretinal fibrosis and choroidal neovascularization in Vogt-Koyanagi-Harada syndrome. Graefes Arch Clin Exp Ophthalmol 1999;237:1039–1045.
Read RW, Rao NA, Cunningham ET. Vogt-Koyanagi-Harada disease. Curr Opin Ophthalmol 2000;11:437–442.
Moorthy RS, Chong LP, Smith RE, Rao NA. Subretinal neovascular membranes in Vogt-Koyanagi-Harada syndrome. Am J Ophthalmol 1993;116:164–170.
Bhatnagar P, Freund KB, Spaide RF, et al. Intravitreal bevacizumab for the management of choroidal neovascularization in pseudoxanthoma elasticum. Retina 2007;27:897–902.
Adan A, Navarro M, Casaroli-Marano RP, et al. Intravitreal bevacizumab as initial treatment for choroidal neovascularization associated with presumed ocular histoplasmosis syndrome. Graefes Arch Clin Exp Ophthalmol 2007;245:1873–1875.
Mandal S, Venkatesh P, Sampangi R, Garg S. Intravitreal bevacizumab (Avastin) as primary treatment for myopic choroidal neovascularization. Eur J Ophthalmol 2007;17:620–626.
Inomata H, Minei M, Taniguchi Y, Nishimura F. Choroidal neovascularization in long-standing case of Vogt-Koyanagi-Harada disease. Jpn J Ophthalmol 1983;27:9–26.
Foster RE, Knight CD, Lowder CY. Subfoveal choroidal neovas cular membrane excision in Vogt-Koyanagi-Harada syndrome. Retina 2000;20:547–549.
Farah ME, Costa RA, Muccioli C, et al. Photodynamic therapy with verteporfin for subfoveal choroidal neovascularization in Vogt-Koyanagi-Harada syndrome. Am J Ophthalmol 2002;134:137–139.
Nowilaty SR, Bouhaimed M. Photodynamic therapy for subfoveal choroidal neovascularisation in Vogt-Koyanagi-Harada disease. Br J Ophthalmol 2006;90:982–986.
Ketata A, Ben Zina Z, Hajji D, et al. Two cases of subretinal neovascular membrane in Vogt-Koyanagi-Harada syndrome [in French]. J Fr Ophtalmol 2006;29:302–306.
Pedersen R, Soliman W, Lund-Andersen H, Larsen M. Treatment of choroidal neovascularization using intravitreal bevacizumab. Acta Ophthalmol Scand 2007;85:526–533.
Adamis AP, Shima DT. The role of vascular endothelial growth factor in ocular health and disease. Retina 2005;25:111–118.
Author information
Authors and Affiliations
Corresponding author
About this article
Cite this article
Wu, L., Evans, T., Saravia, M. et al. Intravitreal bevacizumab for choroidal neovascularization secondary to Vogt-Koyanagi-Harada syndrome. Jpn J Ophthalmol 53, 57–60 (2009). https://doi.org/10.1007/s10384-008-0600-4
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10384-008-0600-4